Overexpression of the human major vault protein in astrocytic brain tumor cells
W Berger1, S Spiegl-Kreinecker, J Buchroithner
1Institute of Cancer Research, Division of Applied and Experimental Oncology, Borschke gasse 8a Vienna University, Vienna, Austria. walter.berger@univie.ac.at
Abstract:
Evidence has shown that the major human vault protein (MVP), which is identical to lung resistance-related protein (LRP), may be causally involved in a special type of multidrug resistance (MDR). The purpose of this study was to investigate the expression and cellular localization of MVP in cells derived from brain tumors and other tumors of neuroectodermal origin. Using both established cell lines (n = 22) and primary explants (n = 30), we show that a distinct overexpression of the MVP gene at the mRNA (RT-PCR) and protein (Western blot) levels is a characteristic feature of cells derived from astrocytic brain tumors. Primary cultures obtained from meningioma specimens also expressed high MVP levels, in contrast to neuroblastoma and medulloblastoma cells, which rarely contained detectable amounts of MVP. Normal human astrocytes cultured in vitro expressed MVP, although at low amounts compared with most malignant cell types. Basal MVP expression correlated with resistance against diverse antineoplastic drugs including anthracyclins, cisplatin and etoposide. By Western blot, MVP was also detected in all tumor samples taken from 7 glioma and 3 meningioma patients. Taken together, these data suggest overexpression of MVP as one explanation for the low efficacy of chemotherapeutic treatment of astrocytic brain tumors.
Insights
Overexpression of the major vault protein (MVP) is characteristic of astrocytic brain tumors, contributing to multidrug resistance (MDR). This finding may explain the limited efficacy of chemotherapy for these challenging cancers.
Area of Science:
- Oncology
- Molecular Biology
- Neuroscience
Background:
- The major human vault protein (MVP), also known as lung resistance-related protein (LRP), is implicated in multidrug resistance (MDR).
- Understanding MVP's role in brain tumors is crucial for improving treatment outcomes.
Purpose of the Study:
- To investigate the expression and cellular localization of MVP in brain tumors and neuroectodermal-derived tumors.
- To correlate MVP expression levels with drug resistance in these cell types.
Main Methods:
- Utilized established cell lines (n=22) and primary explants (n=30) from various tumors.
- Assessed MVP gene expression via mRNA (RT-PCR) and protein (Western blot) analysis.
- Analyzed tumor samples from glioma and meningioma patients.
Main Results:
- Distinct overexpression of MVP mRNA and protein was observed in astrocytic brain tumor cells.
- High MVP levels were found in meningioma cultures, but rarely in neuroblastoma and medulloblastoma.
- Basal MVP expression correlated with resistance to anthracyclins, cisplatin, and etoposide.
Conclusions:
- MVP overexpression is a hallmark of astrocytic brain tumors.
- Elevated MVP levels may contribute to the observed chemotherapeutic resistance in these tumors.
- Targeting MVP could potentially enhance treatment efficacy for astrocytic brain tumors.
Related Concept Videos
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Abnormal Proliferation

